近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-11 | 55.84 0.18% | | -2958.22万 | -14.33% | -486.50万 | -2.36% | 3444.72万 | - 16.69% | | 2025-09-10 | 55.74 0.02% | | -551.75万 | -3.48% | 391.93万 | 2.47% | 159.82万 | 1.01% | | 2025-09-09 | 55.73 -4.31% | | 901.60万 | 3.32% | 676.73万 | 2.49% | -1578.32万 | -5.82% | | 2025-09-08 | 58.24 | 7.08% | 4161.88万 | 9.45% | -141.05万 | -0.32% | -4020.83万 | -9.13% | | 2025-09-05 | 54.3 ...

证券之星消息，截至2025年9月10日收盘，大博医疗(002901)报收于55.74元，上涨0.02%，换手率 0.98%，成交量2.84万手，成交额1.58亿元。 9月10日的资金流向数据方面，主力资金净流出551.75万元，占总成交额3.48%，游资资金净流入391.93 万元，占总成交额2.47%，散户资金净流入159.82万元，占总成交额1.01%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净流入 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-10 | 55.74 0.02% | | -551.75万 | -3.48% | 391.93万 | 2.47% | 159.82万 | liv 1.01% | | 2025-09-09 | 55.73 -4.31% | | ● 901.60万 | 3.32% | 676.73万 | 2.49% | -1578.32万 | -5.82% | | 2025-09-08 | 58. ...

从大博医疗十大流通股东角度 9月9日，大博医疗跌5.05%，截至发稿，报55.30元/股，成交2.52亿元，换手率1.54%，总市值228.95亿 元。 资料显示，大博医疗科技股份有限公司位于福建省厦门市海沧区山边洪东路18号，成立日期2004年8月 12日，上市日期2017年9月22日，公司主营业务涉及医用高值耗材的生产、研发与销售。主营业务收入 构成为：创伤类产品38.68%，脊柱类产品17.95%，微创外科类产品16.34%，关节类产品10.37%，其他 产品9.27%，神经外科类产品4.50%，齿科类产品2.89%。 数据显示，南方基金旗下1只基金位居大博医疗十大流通股东。南方中证1000ETF（512100）二季度增 持14.19万股，持有股数75.68万股，占流通股的比例为0.26%。根据测算，今日浮亏损失约222.49万元。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 南方中证1000ETF（512100）基金经理为崔蕾。 截至发稿， ...

Group 1 - The medical device sector is experiencing significant growth, with the CSI All Index Medical Device Index (H30217) rising by 3.31% as of September 8, 2025, and key stocks such as United Imaging Healthcare (688271) increasing by 11.64% [1] - The Medical Device ETF (159883) has seen a notable increase of 8.06 billion CNY in scale over the past month, ranking it among the top 25% of comparable funds [2] - The launch of the "5G Brain-Heart Mobile" platform represents a major breakthrough in the field of brain health, marking the first clinical application of a brain-machine interface for Alzheimer's disease [3] Group 2 - The Chinese medical device industry is poised for international expansion, particularly in the European market, which is valued at 160 billion euros in 2023, with steady growth expected [4] - The medical device sector is anticipated to grow in 2025, driven by increased bidding activity for imaging equipment and supportive policies for home medical devices, alongside accelerated international expansion [4] - The medical device ETF (159883) is the largest in the A-share market, covering various segments including medical equipment and consumables, and is positioned for efficient trading [5]

Group 1 - The medical device sector experienced a significant upward movement on September 8, with companies such as Aojing Medical, United Imaging Medical, and Kaili Medical seeing stock increases of over 10% [1] - Other companies in the sector, including Jimin Health, BGI Genomics, Dabo Medical, and Mindray Medical, also showed positive stock performance [1]

证券之星消息，截至2025年9月5日收盘，大博医疗(002901)报收于54.39元，上涨1.76%，换手率 1.03%，成交量2.98万手，成交额1.61亿元。 9月5日的资金流向数据方面，主力资金净流出533.02万元，占总成交额3.32%，游资资金净流出488.96 万元，占总成交额3.04%，散户资金净流入1021.98万元，占总成交额6.36%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-05 | 54.39 1.76% | | -533.02万 | -3.32% | -488.96万 | -3.04% | 1021.98万 | - 6.36% | | 2025-09-04 | 53.45 -1.93% | | -811.77万 | -4.80% | -662.88万 | -3.92% | 1474.64万 | 8.72% | | 2025-09-03 | 54. ...

| | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-04 | 53.45 | -1.93% | -811.77万 | -4.80% | -662.88万 | -3.92% | 1474.64万 | 8.72% | | 2025-09-03 | | 54.50 -0.02% | -1576.55万 | -10.98% | 1110.52万 | 7.74% | 466.02万 | 3.25% | | 2025-09-02 | 54.51 | -2.28% | -1953.17万 | -9.66% | -431.68万 | -2.14% | 2384.84万 | 11.80% | | 2025-09-01 | 55.78 | 1.38% | 405.47万 | 1.65% | 859.24万 | 3.51% | -1264.71万 | -5.16% | | 2025-08-29 | 55.02 | 1.40% | - ...

Core Insights - The Chinese medical device industry faced challenges and opportunities in the first half of 2025, with a recovery in bidding for medical equipment not yet translating into improved company performance [1][3] - Overall performance of the industry remained under pressure due to complex global macroeconomic conditions, with a decline in revenue and net profit for A-share medical device companies [1][3] Financial Performance - In the first half of 2025, 131 A-share medical device companies reported total revenue of 1188.17 billion yuan, a decrease of 4.29% from 1241.43 billion yuan in the previous year [1] - Net profit for these companies fell to 188.12 billion yuan, down 17.17% from 227.11 billion yuan year-on-year [1] - Over 80% of companies in the in vitro diagnostics sector experienced a decline in performance due to factors like centralized procurement and medical insurance cost control [1] Sector Highlights - Despite overall declines, certain sectors like orthopedics and cardiovascular devices showed significant growth, with companies such as Sanyou Medical and Dabo Medical reporting revenue growth exceeding 40% [1][4] - Sanyou Medical achieved a remarkable net profit growth of 2083.64%, driven by acquisitions and recovery in domestic business [4] International Market Expansion - Overseas markets have become crucial for leading companies to overcome growth bottlenecks, with companies like Ruimai Te and Yuyue Medical reporting revenue growth of 61.33% and 49.96% respectively from international sales [2][7] - The international revenue for 89 companies reached 332.47 billion yuan, marking an 8.2% increase year-on-year [6] Future Outlook - The industry anticipates a turning point in the second half of 2025, with signs of demand recovery and improved bidding activity for medical devices [3][10] - The approval of innovative medical devices and drugs is on the rise, with 45 innovative medical devices approved in the first half of 2025, a year-on-year increase of 87% [12][13]

证券之星消息，截至2025年9月1日收盘，大博医疗(002901)报收于55.78元，上涨1.38%，换手率 1.53%，成交量4.41万手，成交额2.45亿元。 9月1日的资金流向数据方面，主力资金净流入405.47万元，占总成交额1.65%，游资资金净流入859.24 万元，占总成交额3.51%，散户资金净流出1264.71万元，占总成交额5.16%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-09-01 | 55.78 | 1.38% | 405.47万 | 1.65% | 859.24万 | 3.51% | -1264.71万 | -5.16% | | 2025-08-29 | 55.02 | 1.40% | = -91.04万 | -0.49% | -165.65万 | -0.89% | 256.69万 | 1.38% | | 2025-08-28 | | 54.26 ...

Policy Developments - The State Council aims to develop the China (Jiangsu) Pilot Free Trade Zone into a globally influential biopharmaceutical industry hub, with a plan that includes 18 key tasks for integrated innovation across the entire industry chain by 2030 [1] Drug Approvals - China Resources Double Crane announced that its subsidiaries received drug registration certificates for three products, which will enhance the company's product line and market competitiveness [2] - Tianyao Pharmaceutical's subsidiary received a drug registration certificate for a new eye drop product, which is expected to positively impact the company's domestic market expansion and performance [3] Financial Reports - China National Pharmaceutical Group reported a revenue of 17.076 billion yuan for the first half of 2025, a decrease of 6.71% year-on-year, with a net profit of 294 million yuan, down 16.19% [4] - Jiahe Meikang reported a revenue of 219 million yuan for the first half of 2025, a decline of 27.22%, resulting in a net loss of 116 million yuan [5] - Renfu Pharmaceutical reported a revenue of 12.064 billion yuan, a decrease of 6.20%, but a net profit increase of 3.92% to 1.155 billion yuan [6] Investment Activities - Tibet Pharmaceutical plans to invest 60 million USD in Accuredit Therapeutics Limited, acquiring a 40.82% stake, focusing on gene editing technologies [7] Industry Developments - The first long-acting injection for infertility treatment has been approved, providing a more efficient and convenient option for patients compared to traditional daily injections [8] - A study revealed a protein linked to infertility and cancer, suggesting potential new treatment avenues for both conditions [9] Shareholder Actions - Dabo Medical announced a plan for a shareholder to reduce their stake by up to 2% of the company's shares [10] - Kangchen Pharmaceutical's executive plans to sell up to 87,500 shares due to personal financial needs [11]